SCHEMBL6461145

SCHEMBL6461145

COc1ccc2c(c1)C(CC(N)=O)CC2=O

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.53
PDE5A O76074 1/20 0.53
LMNA P02545 1/20 0.51
GAA P10253 1/20 0.51
TNKS O95271 4/20 0.49
PSMB5 P28074 1/20 0.48
PARP1 P09874 3/20 0.48
TNKS2 Q9H2K2 3/20 0.48
PARP10 Q53GL7 1/20 0.48
MTNR1A P48039 1/20 0.46
MTNR1B P49286 1/20 0.46
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
FFAR1 O14842 1/20 0.42
CYP19A1 P11511 5/20 0.41
METAP1 P53582 2/20 0.41
MAOB P27338 2/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL503654 0.88 SIGMAR1 (0.57) SIGMAR1PDE5ALMNAGAATNKS
SCHEMBL1207853 0.86 SIGMAR1 (0.56) SIGMAR1PDE5ALMNAGAATNKS
SCHEMBL13485788 0.84 PDE5A (0.67) SIGMAR1PDE5ALMNAGAATNKS
SCHEMBL10163625 0.83 LMNA (0.51) SIGMAR1PDE5ALMNAGAATNKS
SCHEMBL2419303 0.79 LMNA (0.48) SIGMAR1PDE5ALMNAGAATNKS
SCHEMBL7564413 0.79 HTR2C (0.39) SIGMAR1PDE5APSMB5MAOB
SCHEMBL15724892 0.78 LMNA (0.50) SIGMAR1PDE5ALMNAGAATNKS
SCHEMBL5679577 0.78 LMNA (0.47) SIGMAR1PDE5ALMNAGAATNKS
SCHEMBL16416391 0.77 FFAR1 (0.64) SIGMAR1PDE5ALMNAGAAPSMB5
SCHEMBL14943360 0.76 PSMB5 (0.54) SIGMAR1PDE5ALMNAGAATNKS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 SIGMAR1 283/4885PDE5A 1134/4885LMNA 3391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.